GALNT9 Gene Expression Is a Prognostic Marker in Neuroblastoma Patients | Zendy

Nora Berois | Zendy; CharlesHenry Gattolliat | Zendy; Enrique Barrios | Zendy; Laura Capandeguy | Zendy; Sétha DoucRasy | Zendy; Dominique ValteauCouanet | Zendy; Jean Bénard | Zendy; Eduardo Osinaga | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

GALNT9 Gene Expression Is a Prognostic Marker in Neuroblastoma Patients

Author(s) -

Nora Berois,

CharlesHenry Gattolliat,

Enrique Barrios,

Laura Capandeguy,

Sétha DoucRasy,

Dominique ValteauCouanet,

Jean Bénard,

Eduardo Osinaga

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2012.192328

Subject(s) - neuroblastoma , biology , cancer research , oncology , neuroblast , gene , gene expression , proportional hazards model , medicine , cohort , cell culture , genetics , neurogenesis

The enzymes encoded by the GALNT [UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GALNAC-T)] gene family catalyze the first step of O-glycosylation. Little is known about the link between expression of the genes encoding GALNAC-T enzymes and tumor progression in neuroblastoma, a pediatric cancer that can be classified as either low or high risk. We assessed the expression of genes in the GALNT family in a large cohort of neuroblastoma patients and characterized members of this family that might be used as new prognostic markers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research